We are live on ! Find out more
SCNI icon

Scinai Immunotherapeutics

12 hedge funds and large institutions have $21.1M invested in Scinai Immunotherapeutics in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more capital inflows, than outflows

Capital inflows: $4.3M | Capital outflows: $2.01M

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

33% more funds holding

Funds holding: 9 → 12 (+3)

0.18% more ownership

Funds ownership: 2.74% → 2.92% (+0.18%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
12
Holders Change
+3
Holders Change %
+33.33%
% of All Funds
0.24%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
2
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SCNI Hedge Fund Activity: Q3 2020 in Review

12 of the 4,973 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2020, worth a combined $21.1M — up 83% from $11.5M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new SCNI positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $1.69M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.22M sold.

  • 12 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2020, up from 9 in Q2 2020.
  • Funds reported $21.1M of Scinai Immunotherapeutics stock for Q3 2020, up 83% quarter-over-quarter.
  • 6 funds opened new Scinai Immunotherapeutics positions in Q3 2020 and 3 closed out, a net change of +3 holders.
  • The largest Scinai Immunotherapeutics buyer in Q3 2020 was Morgan Stanley, an estimated $1.69M added.
  • The largest Scinai Immunotherapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $1.22M sold.

Based on aggregated 13F filings for Q3 2020.